Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Ranibizumab + PRP vs PRP in high‑risk proliferative diabetic retinopathy
2009-014409-15Phase 2Completed
- Sponsor
- AIBILI
- Start
- Sep 2009
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ranibizumab in proliferative diabetic retinopathy (PDR) (3 arms), sponsored by AIBILI. Primary endpoint: Regression of retinal neovascularization. Started Sep 2009; status: completed.
02
Drugs
ranibizumab
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2009-014409-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014409-15.